SemBioSys Completes pre-IND Meeting with U.S. FDA for APO AIMilano
News Aug 12, 2009
SemBioSys Genetics Inc. has announced that it has received the minutes of a successful and productive pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding Apo AIMilano, a next-generation cardiovascular drug.
The meeting focused on the development plans for Apo AIMilano, during which the FDA confirmed SemBioSys’ development strategy necessary to file an IND application and addressed the proposed design of clinical trials for Apo AIMilano.
“We are encouraged by the feedback we have received from the FDA, particularly in regard to our development plan required to advance Apo AIMilano to clinical trials. This will be the second pharmaceutical candidate to be studied in human clinical trials produced using SemBioSys’ plant-based production system,” said James Szarko, Chief Executive Officer of SemBioSys. “Because of its unique ability to promote plaque regression, Apo AIMilano has the potential to revolutionize clinical practice and significantly improve outcomes in patients with cardiovascular disease.”
In collaboration with leading cardiologists and cardiovascular researchers, SemBioSys has confirmed the activity of plant-derived Apo AIMilano in seven preclinical models.
The Company has demonstrated the anti-atherosclerotic effects of Apo AIMilano based on cholesterol mobilization from the arterial wall, lipid content of atherosclerotic plaques, and the reduction of overall volume of atherosclerotic plaque after multiple injections.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018